top
Search terms
Results 1 - 10 of 12 - ordered by :
Pages: 1 2
Romanianjournal

E-mail: jill.pell@glasgow.ac.uk Global risk scores use individual level information on non-modifiable risk factors (such as age, sex, ethnicity and family history) and modifiable risk factors (such ...

Date : 08/07/2016
Ejhf

In 2009, the HEAAL investigators[1] reported that losartan 150 mg/day reduced the rate of death and admissions for heart failure with reduced ejection fraction (HFREF) compared with patients ...

European Journal of Heart Failure, Pitt, Bertram

Date : 01/12/2012 Item size : 72879 bytes
Ehjournal

Abstract Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9, ...

European Heart Journal, Coronary artery disease, Christopher P. Cannon, Bertrand Cariou, Dirk Blom, James M. McKenney, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, Helen M. Colhoun

Date : 14/05/2015
Ehjournal

Abstract Aims On the basis of the JUPITER trial, European health authorities recently approved the use of rosuvastatin to reduce first major cardiovascular events among high' global risk primary ...

European Heart Journal, Koenig, Wolfgang, Ridker, Paul M

Date : 01/01/2011 Item size : 264590 bytes
Ehjournal

Abstract Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9, ...

European Heart Journal, Cannon, Christopher P., Cariou, Bertrand, Blom, Dirk, McKenney, James M., Lorenzato, Christelle, Pordy, Robert, Chaudhari, Umesh, Colhoun, Helen M.

Date : 14/05/2015 Item size : 271307 bytes
Ehjournal

[...]at approval, the relation between non-cardiovascular benefit and cardiovascular risk may not be adequately defined. Deficiencies of pre-approval data are exemplified by issues emerging from the ...

European Heart Journal, Borer, Jeffrey S., Pouleur, Hubert, Abadie, Eric, Follath, Ferrenc, Wittes, Janet, Pfeffer, Marc A., Pitt, Bertram, Zannad, Faiez

Date : 01/08/2007 Item size : 216749 bytes
Ehjournal

Abstract Aims On the basis of the JUPITER trial, European health authorities recently approved the use of rosuvastatin to reduce first major cardiovascular events among high' global risk primary ...

European Heart Journal, Koenig, Wolfgang, Ridker, Paul M

Date : 01/01/2011
Ehjournal

[...]at approval, the relation between non-cardiovascular benefit and cardiovascular risk may not be adequately defined. Deficiencies of pre-approval data are exemplified by issues emerging from the ...

European Heart Journal, Borer, Jeffrey S., Pouleur, Hubert, Abadie, Eric, Follath, Ferrenc, Wittes, Janet, Pfeffer, Marc A., Pitt, Bertram, Zannad, Faiez

Date : 01/08/2007
Ejhf

In 2009, the HEAAL investigators[1] reported that losartan 150 mg/day reduced the rate of death and admissions for heart failure with reduced ejection fraction (HFREF) compared with patients ...

European Journal of Heart Failure, Pitt, Bertram

Date : 01/12/2012 Item size : 73513 bytes
Ehjournal

Abstract Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9, ...

European Heart Journal, Cannon, Christopher P., Cariou, Bertrand, Blom, Dirk, McKenney, James M., Lorenzato, Christelle, Pordy, Robert, Chaudhari, Umesh, Colhoun, Helen M.

Date : 14/05/2015 Item size : 353183 bytes